Literature DB >> 1712772

TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.

D A Kujubu1, B S Fletcher, B C Varnum, R W Lim, H R Herschman.   

Abstract

TIS10 is a primary response gene whose cDNA was cloned as a result of its rapid, superinducible expression in Swiss 3T3 cells in response to 12-O-Tetradecanoylphorbol-13-acetate. The 5'-untranslated region of the 3.9-kilobase TIS10 message contains only 124 nucleotides, whereas the 3'-untranslated region is almost 2 kilobases in length. Within this long 3' region, there are multiple repeats of the sequence ATTTA, a sequence often present in rapidly degraded mRNA species. Primer extension revealed that the TIS10 cDNA begins 16 base pairs downstream of the transcription start site for the TIS10 gene. The TIS10 cDNA encodes a predicted protein of 604 amino acids. A computer search identified striking similarities between the predicted TIS10 protein product and the murine, sheep, and human prostaglandin synthase/cyclooxygenase proteins. The TIS10 protein has many of the same conserved amino acids that are thought to be important for cyclooxygenase function. TIS10 mRNA is undetectable by Northern analysis in quiescent 3T3 cells. The TIS10 gene is rapidly and transiently induced by forskolin and serum, as well as by 12-O-tetradecanoylphorbol-13-acetate, in Swiss 3T3 cells. These agents elicit far more dramatic changes in TIS10 mRNA levels than in cyclooxygenase mRNA levels. The expression of the TIS10 gene appears to be highly cell type-restricted in cultured cell lines; of 12 cell lines tested under superinducing conditions, only the rodent embryonic Swiss 3T3 and Rat1 cell lines expressed TIS10 gene.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712772

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  246 in total

1.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 2.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 3.  Regulated formation of eicosanoids.

Authors:  F A Fitzpatrick; R Soberman
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 4.  Rheumatology: 7. Basics of therapy.

Authors:  S H Huang
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

Review 5.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 6.  Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?

Authors:  Timothy D Warner; Jane A Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

7.  Effect of topically applied cyclooxygenase-2-selective inhibitors on arachidonic acid- and tetradecanoylphorbol acetate-induced dermal inflammation in the mouse.

Authors:  V Puigneró; J Queralt
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

8.  Fish macrophages express a cyclo-oxygenase-2 homologue after activation.

Authors:  J Zou; N F Neumann; J W Holland; M Belosevic; C Cunningham; C J Secombes; A F Rowley
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

Review 9.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

Review 10.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.